company background image
XERS

Xeris Biopharma Holdings NasdaqGS:XERS Stock Report

Last Price

US$1.58

Market Cap

US$214.8m

7D

-1.9%

1Y

n/a

Updated

28 Sep, 2022

Data

Company Financials +
XERS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

XERS Stock Overview

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology.

Xeris Biopharma Holdings, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Xeris Biopharma Holdings
Historical stock prices
Current Share PriceUS$1.58
52 Week HighUS$3.17
52 Week LowUS$1.25
Beta0
1 Month Change-5.95%
3 Month Change2.60%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-33.05%

Recent News & Updates

Aug 09

Xeris Pharmaceuticals Q2 2022 Earnings Preview

Xeris Pharmaceuticals (NASDAQ:XERS) is scheduled to announce Q2 earnings results on Wednesday, August 10th, before market open. The consensus EPS Estimate is -$0.22 (-4.8% Y/Y) and the consensus Revenue Estimate is $25.53M (+155.3% Y/Y). Over the last 2 years, XERS has beaten EPS estimates 63% of the time and has beaten revenue estimates 88% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 3 downward. Revenue estimates have seen 2 upward revisions and 1 downward.

Aug 01

Xeris amends commercial terms for hypoglycemia therapy as partner inks buyout deal

Xeris Biopharma (NASDAQ:XERS) announced on Monday that the terms of its commercialization agreement for hypoglycemia therapy Ogluo would change as UK-based Arecor Therapeutics has agreed to acquire its partner Tetris Pharma. In July 2021, Xeris (XERS) joined hands with Tetris to commercialize Ogluo in the European Economic Area, U.K., and Switzerland for severe hypoglycemia in patients with diabetes mellitus. Per the terms of the buyout deal, Arecor has agreed to continue the sales of Ogluo in EEA and the U.K. even after the acquisition. However, the deal includes an amendment to the 16-year minimum term license and supply agreements for Ogluo sales in the region. Accordingly, Xeris (XERS) is entitled to mid-single-digit royalty on net sales of the therapy in addition to one-off commercial milestone payments if net revenues for a particular year exceed pre-defined thresholds.  The initial agreement between Xeris (XERS) and Tetris for Ogluo was worth as much as $71M.

Shareholder Returns

XERSUS PharmaceuticalsUS Market
7D-1.9%3.7%-2.0%
1Yn/a5.3%-20.3%

Return vs Industry: Insufficient data to determine how XERS performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how XERS performed against the US Market.

Price Volatility

Is XERS's price volatile compared to industry and market?
XERS volatility
XERS Average Weekly Movement9.9%
Pharmaceuticals Industry Average Movement11.5%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: XERS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: XERS's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005294Paul Edickhttps://www.xerispharma.com

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect.

Xeris Biopharma Holdings, Inc. Fundamentals Summary

How do Xeris Biopharma Holdings's earnings and revenue compare to its market cap?
XERS fundamental statistics
Market CapUS$214.81m
Earnings (TTM)-US$136.70m
Revenue (TTM)US$79.87m

2.7x

P/S Ratio

-1.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
XERS income statement (TTM)
RevenueUS$79.87m
Cost of RevenueUS$18.99m
Gross ProfitUS$60.88m
Other ExpensesUS$197.57m
Earnings-US$136.70m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.01
Gross Margin76.22%
Net Profit Margin-171.15%
Debt/Equity Ratio186.7%

How did XERS perform over the long term?

See historical performance and comparison